SPP1 and Duchenne muscular dystrophy: All of this happens under the complex influences of endogenous steroid hormones and exogenous therapeutic corticosteroids, so that SPP1 genotype may be considered as a pharmacodynamic biomarker of the GC treatment response in DMD.